Home > Haematology > EHA 2020 > Myeloid > Patients with lower-risk MDS benefit from imetelstat

Patients with lower-risk MDS benefit from imetelstat

Presented By
Prof. Uwe Platzbecker, University Clinic Leipzig, Germany
EHA 2020
Phase 2, IMerge
Patients with Low or Intermediate-1 risk myelodysplastic syndrome (lower-risk MDS) experienced meaningful and durable transfusion independence when treated with imetelstat. Prof. Uwe Platzbecker (University Clinic Leipzig, Germany) presented the phase 2 results from the phase 2-3 IMerge clinical trial [1]. IMerge evaluated the novel telomerase inhibitor imetelstat as a treatment for patients with lower-risk MDS, who had relapsed after or were refractory to treatment with erythropoiesis-stimulating agents (ESAs). The primary efficacy endpoint of IMerge was 8-week RBC transfusion independence (RBC-TI) rate, for any 8 consecutive weeks since trial entry. Key secondary endpoints included rate of haematologic improvement-erythroid (HI-E) and duration of TI. In the open label, single arm, phase 2 stage of IMerge, 38 patients were treated with imetelstat, with a me...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on